Valhi, Inc. Q1 2010 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2010. Valhi, Inc. operates as a holding company with three primary consolidated segments: Chemicals (majority-owned Kronos Worldwide, Inc., producing titanium dioxide), Component Products (majority-owned CompX International, Inc., manufacturing security and ergonomic products), and Waste Management (wholly-owned Waste Control Specialists LLC, handling hazardous and radioactive waste). The company is majority-owned by Contran Corporation.
Key Financial Metrics
| Metric (in millions) | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $356.8 | $277.3 |
| Net Income (Loss) | $15.1 | $(23.4) |
| Net Income Attributable to Valhi | $13.6 | $(20.0) |
| Diluted EPS | $0.10 | $(0.18) |
| Operating Cash Flow | $(16.5) Used | $(18.8) Used |
| Total Debt | $998.1 | $990.9 |
| Cash and Equivalents | $46.3 | $68.7 |
Material Changes vs. Prior Period
- Turnaround to Profitability: The company reported a net income of $13.6 million attributable to stockholders, reversing a $20.0 million loss in the prior year. This was primarily driven by a non-cash income tax benefit of $35.2 million related to a favorable European Court ruling on German tax issues.
- Revenue Growth: Net sales increased 29% to $356.8 million, driven by a 26% increase in TiO2 sales volumes and favorable currency impacts.
- Segment Performance:
- Chemicals: Operating income improved from a $25.5 million loss to a $22.6 million gain due to higher production volumes and lower unabsorbed fixed costs.
- Component Products: Operating income turned positive ($1.7 million) from a loss ($1.0 million) due to improved gross margins, partially offset by patent litigation expenses.
- Waste Management: Continued to report an operating loss of $6.7 million.
- Unusual Items: The quarter included a $33.3 million litigation settlement and contract termination expense (related to NL Industries and WCS) and $18.2 million in insurance recoveries. In contrast, Q1 2009 included a $11.9 million litigation settlement gain and a $6.4 million gain on the sale of a business.
Guidance, Outlook, and Risks
- 2010 Outlook: Management expects to report net income for the full year 2010, driven by operating income from the Chemicals and Component Products segments and the recognized tax benefit. They anticipate higher TiO2 selling prices and near-full capacity utilization for the remainder of the year.
- Capital Expenditures: Estimated at $89 million for 2010, with $42 million allocated to the Waste Management segment for the construction of a low-level radioactive waste facility expected to be operational in early 2011.
- Liquidity: The company maintains $97.6 million in available credit and $98.5 million in cash and marketable securities. Management believes liquidity is sufficient to meet short-term obligations.
- Risks and Contingencies:
- Litigation: Significant exposure remains regarding lead pigment and asbestos litigation involving NL Industries. While no accruals are currently made for pending lead pigment cases, outcomes could materially impact financial results.
- Environmental: Ongoing remediation obligations exist for various sites, with estimated costs potentially exceeding current accruals.
- Patent Disputes: CompX is involved in patent litigation with Humanscale Corporation; while a jury awarded CompX over $19 million in damages, the verdict is subject to appeal and no receivable has been accrued.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the permanence of the $35.2 million German tax benefit and the company's ability to utilize remaining German net operating loss carryforwards.
- Litigation Exposure: Review the status of NL Industries' lead pigment and asbestos litigation to assess potential future liabilities not currently accrued.
- Waste Management Viability: Monitor the progress of the low-level radioactive waste facility construction and the ability to secure financing, as this segment continues to operate at a loss.
- CompX Patent Litigation: Track the appeal process regarding the $19 million jury award against Humanscale to determine if the amount will be realized.
- Debt Covenants: Confirm continued compliance with debt covenants, particularly for CompX, which faced borrowing restrictions due to cumulative losses in the first quarter.